Compare MFM & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFM | CRBP |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | 36 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.5M | 190.3M |
| IPO Year | N/A | 2014 |
| Metric | MFM | CRBP |
|---|---|---|
| Price | $5.34 | $10.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 287.2K | ★ 343.4K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $178.67 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $5.07 | $7.12 |
| 52 Week High | $5.67 | $20.56 |
| Indicator | MFM | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 39.31 | 59.38 |
| Support Level | $5.23 | $8.30 |
| Resistance Level | $5.47 | $10.74 |
| Average True Range (ATR) | 0.06 | 0.54 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 68.27 |
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but it may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.